Özet
Romatoid artrit, bağışıklık sisteminin süreğen aktivasyonu ve ilerleyici eklem hasarı ile karakterize kronik bir enflamatuvar hastalıktır. Geleneksel ve biyolojik hastalık modifiye edici antiromatizmal ilaçlar hastalık kontrolünü önemli ölçüde iyileştirmiş olsa da, tedaviye direnç ve sürekli remisyon elde edilememesi önemli klinik zorluklar olmaya devam etmektedir. Bu derleme makalesi, romatoid artritte klinik etkinliği, güvenlik profili ve terapötik potansiyeline odaklanarak, seçici bir Janus kinaz 1 inhibitörü olan filgotinibi değerlendirmektedir. Klinik çalışmalar, filgotinibin orta ila şiddetli romatoid artritli hastalarda, özellikle metotreksat veya biyolojik tedavilere yetersiz yanıt veren veya intoleransı olanlarda hızlı ve sürekli klinik faydalar sağladığını göstermiştir. En sık bildirilen yan etkiler arasında hafif enfeksiyonlar ve nazofarenjit yer alırken, genel tolere edilebilirlik olumlu kalmaktadır. Genel olarak, filgotinib, tedavisi zor romatoid artritli hastalar için iyi tolere edilen hedefe yönelik bir tedavi seçeneğidir. Bununla birlikte, güvenlik profilini daha iyi tanımlamak ve güncel tedavi stratejileri içindeki en uygun konumunu netleştirmek için daha uzun vadeli çalışmalara ve gerçek dünya verilerine ihtiyaç duyulmaktadır.
Anahtar Kelimeler:
Advers etkiler, DMARD direnç, filgotinib, JAK1 inhibitörü
Kaynaklar
1
Cao G, Luo Q, Wu Y, Chen G. Inflammatory bowel disease and rheumatoid arthritis share a common genetic structure. Front Immunol. 2024;15:1-13.
2
Brown P, Pratt AG, Hyrich KL. Therapeutic advances in rheumatoid arthritis. BMJ. 2024;e070856.
3
Radu A-F, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10:2857.
4
Park JJ. Mechanism-based drug therapy of inflammatory bowel disease with special reference to rheumatic disease. J Rheum Dis. 2020;27:128-35.
5
Roodenrijs NMT, Welsing PMJ, van Roon J, et al. Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. Rheumatology. 2022;61:3552-66.
6
Greenhalgh T, Thorne S, Malterud K. Time to challenge the spurious hierarchy of systematic over narrative reviews? Eur J Clin Invest. 2018;48:1-6.
7
Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685-99.
8
Schultz O, Fiehn C, Kneitz C, et al. Real-world experience with filgotinib for rheumatoid arthritis in Germany. Z Rheumatol. 2025;84:39-47.
9
Tanaka Y, Kavanaugh A, Wicklund J, McInnes IB. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: an overview from clinical trials. Mod Rheumatol. 2022;32:1-11.
10
Dhillon S, Keam SJ. Filgotinib: first approval. Drugs. 2020;80:1987-97.
11
Ahmed S, Yesudian R, Ubaide H, Coates LC. Rationale and concerns for using JAK inhibitors in axial spondyloarthritis. Rheumatol Adv Pract. 2024;8: rkae141.
12
Jacob I, Beresford-Hulme L, Butler K, et al. PMS4 comparative efficacy of filgotinib versus alternative treatments for rheumatoid arthritis in patients with an ınadequate response to methotrexate: a systematic review and network meta-analysis. Value Heal. 2020;23:S592.
13
Clarke B, Yates M, Adas M, Bechman K, Galloway J. The safety of JAK-1 inhibitors. Rheumatology. 2021;60(Suppl 2):ii24-30.
14
Raimondo MG, Biggioggero M, Coletto LA, Ramming A, Caporali R, Favalli EG. Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights. Expert Rev Clin Pharmacol. 2021;14:661-70.
15
Kim ES, Keam SJ. Filgotinib in rheumatoid arthritis: a profile of ıts use. Clin Drug Investig. 2021;41:741-9.
16
Namour F, Anderson K, Nelson C, Tasset C. Filgotinib: a clinical pharmacology review. Clin Pharmacokinet. 2022;61:819-32.
17
Anderson K, Hao Z, Oliver M, et al. Thu0117 pharmacokinetics and short-term safety of filgotinib, a selective Janus kinase 1 inhibitor, in subjects with moderate hepatic impairment. Ann Rheum Dis. 2019;78(Suppl 2):331.1-331.
18
European Medicines Agency. Filgotinib (Jyseleca). European Medicines Agency. Filgotinib (Jyseleca). 2025. Available link: https://www.ema.europa.eu/en/medicines/human/EPAR/
19
Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017;76:1009-19.
20
Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80:848-58.
21
Genovese MC, Kalunian K, Gottenberg J-E, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy. JAMA. 2019;322:315.
22
Westhovens R, Rigby WFC, van der Heijde D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;80:727-38.
23
Kavanaugh A, Westhovens RR, Winthrop KL, et al. Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase II rheumatoid arthritis programs. J Rheumatol. 2021;48:1230-8.
24
Gros B, Goodall M, Plevris N, et al. Real-world cohort study on the effectiveness and safety of filgotinib use in ulcerative colitis. J Crohn’s Colitis. 2025;19:jjad187.
25
Raimondo V, Caminiti M, Olivo D, et al. Real-life use of filgotinib in rheumatoid arthritis: a retrospective cohort study. J Clin Med. 2024;13:7185.
26
Maeshima T, Aisu S, Ohkura N, Watanabe M, Itagaki F. The association between deep vein thrombosis, pulmonary embolism, and Janus kinase inhibitors: reporting status and signal detection in the Japanese adverse drug event report database. Drugs - Real World Outcomes. 2024;11:369-75.
27
Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol. 2022;18:301-4.
28
Lee YH, Song GG. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis. Z Rheumatol. 2020;79:785-96.
29
Lee YH, Song GG. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. Z Rheumatol. 2021;80:379-92.
30
Galloway J, Buch MH, Yamaoka K, et al. OP0126 infections and serious infections in the filgotinib rheumatoid arthritis program. Ann Rheum Dis. 2021;80:70-1.
31
Tanaka Y, Matsubara T, Atsumi T, et al. Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: week 156 interim results in FINCH 4. Mod Rheumatol. 2025 [cited 2025 Apr 19];35:425-33.
32
Harnik S, Ungar B, Loebstein R, Ben‐Horin S. A gastroenterologist’s guide to drug interactions of small molecules for inflammatory bowel disease. United Eur Gastroenterol J. 2024;12:627-37.
33
FDA Adverse Event Reporting System (FAERS) Public Dashboard for Drugs and Biologics - FDA Adverse Event Reporting System (FAERS) Public Dashboard for Drugs and Biologics | 2025 [cited 2025 Dec 24]. Available link: https://open.fda.gov/data/faers/
34
Vanhoutte F, Mazur M, Voloshyn O, et al. Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK‐1 inhibitor, after short‐term treatment of rheumatoid arthritis: results of two randomized phase IIa trials. Arthritis Rheumatol. 2017;69:1949-59.
35
Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017;76:998-1008.
36
Mariette X, Borchmann S, Aspeslagh S, et al. Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open. 2025;11:e005033.
37
Anderson K, Xin Y, Zheng H, et al. Filgotinib, a JAK1 inhibitor, has no effect on QT interval in healthy subjects. Clin Pharmacol Drug Dev. 2020;9:32-40.
38
Vallez-Valero L, Gasó-Gago I, Marcos-Fendian Á, et al. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib. Clin Rheumatol. 2023;42:3225-35.
39
Namour F, Desrivot J, Van der Aa A, Harrison P, Tasset C, van’t Klooster G. Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions. Drug Metab Lett. 2016;10:38-48.
40
Hsueh C, Anderson K, Shen G, Yun C, Qin A, Othman AA. Evaluation of the potential drug interactions mediated through P‐gp, OCT2, and MATE1/2K with filgotinib in healthy subjects. Clin Transl Sci. 2022;15:361-70.
41
Begley R, Anderson K, Watkins TR, et al. Lack of drug‐drug interaction between filgotinib, a selective JAK1 inhibitor, and oral hormonal contraceptives levonorgestrel/ethinyl estradiol in healthy volunteers. Clin Pharmacol Drug Dev. 2021;10:376-83.
42
Anderson K, Nelson CH, Gong Q, Alani M, Tarnowski T, Othman AA. Assessment of the effect of filgotinib on the pharmacokinetics of atorvastatin, pravastatin, and rosuvastatin in healthy adult participants. Clin Pharmacol Drug Dev. 2022;11:235-45.
